Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper into the company’s earnings to understand the factors driving its growth.
Abbott Laboratories (NYSE:ABT) reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items, and reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, suggesting confidence in its operations. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58, which suggests management’s confidence in the company’s ability to sustain growth for the remainder of the year.
Bull Case
One of the most prominent highlights of the quarter for investors is Abbott Laboratories’ (NYSE:ABT) diagnostics segment. The company’s cancer diagnostics business, which was recently integrated through the Exact Sciences buyout, is benefiting from an expanding base that comprises both new and repeat users of the colorectal cancer screening test, Cologuard. The quarter’s earnings report corroborates this, as sales in its diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion, emerging as one of the company’s strongest performers during the quarter.
Analysts agree with this sentiment. William Blair stated that the company’s cancer diagnostics results should improve sentiment around the Exact Sciences acquisition, with growth in medical devices helping offset concerns surrounding hospital procedure volumes.
The firm reiterated an Outperform rating on the shares and noted that its shares rose over 10% on fiscal Q2 results, which helps relieve the concerns surrounding the recent Exact Sciences acquisition and medtech end markets and signals an improving nutrition business. It told investors in a research note that all of these updates were positive and should compound with pipeline products for even better results in H2 2026 and into FY27.
What Investors Should Watch Next
While Abbott Laboratories’ (NYSE:ABT) outlook remains encouraging, a meaningful portion of its expected growth acceleration in the second half of 2026 depends on the successful commercialization of several pipeline products. William Blair highlighted the key pipeline products for the company that investors should watch next, including the launch of Amulet 360 late in the year or early in 2027, the ramping-up launch of Volt in the U.S. and TactiFlex Duo OUS, and the potential for Libre reimbursement expansion.
